1. Home
  2. SCOR vs CRDF Comparison

SCOR vs CRDF Comparison

Compare SCOR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

HOLD

Current Price

$4.89

Market Cap

101.6M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.32

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCOR
CRDF
Founded
1999
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.6M
86.8M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
SCOR
CRDF
Price
$4.89
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
44.4K
615.4K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
127.37
27.37
EPS
N/A
N/A
Revenue
$403,549,000.00
$365,993.00
Revenue This Year
$2.75
N/A
Revenue Next Year
$7.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.02
49.61
52 Week Low
$4.60
$0.76
52 Week High
$10.18
$3.31

Technical Indicators

Market Signals
Indicator
SCOR
CRDF
Relative Strength Index (RSI) 40.06 72.12
Support Level $4.60 $1.18
Resistance Level $7.72 $1.43
Average True Range (ATR) 0.39 0.08
MACD 0.06 0.03
Stochastic Oscillator 42.76 93.83

Price Performance

Historical Comparison
SCOR
CRDF

About SCOR comScore Inc.

comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: